VC backs Scout Bio pet gene therapy series A with $9.3m – Animal Pharm
Animal Pharm |
VC backs Scout Bio pet gene therapy series A with $9.3m
Animal Pharm US companion animal gene therapy start-up Scout Bio has snared $9.29 million as part of a series A funding round. Already a subscriber? Please sign in below to continue reading. Sign In. Thanks, we’ve sent a link to reset your password. Forgot your … |
EconoTimes |
Synthetic Biology – A Global Market Overview 2018-2023 …
Business Wire (press release) DUBLIN–(BUSINESS WIRE)–The “Synthetic Biology – A Global Market Overview” report has been added to ResearchAndMarkets.com’s offering. “Synthetic … Synthetic Biology Market Overview, 2018-2023 – Profiles of 36 Companies with Contact Details for 200+ CompaniesPR Newswire (press release) |
PharmaTimes |
Novartis’ CAR–T therapy gets second FDA approval
PharmaTimes The FDA has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic … Two major advances for CAR T-cell cancer treatment6abc.com FDA Approves CAR-T Cell Therapy for Diffuse Large B-Cell …Curetoday.com Novartis and Gilead’s CAR–T Therapies Now Compete for the Same Cancer PatientsLabiotech.eu (blog) Benzinga –MarketWatch –PR Newswire (press release) all 26 news articles » |
Technology Networks |
T Cell Biomarker Predicts Response to CAR T Cell Therapy
Technology Networks Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are … |